Literature DB >> 12874026

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.

Susan M Henshall1, Daniel E H Afar, Jordan Hiller, Lisa G Horvath, David I Quinn, Krishan K Rasiah, Kurt Gish, Dorian Willhite, James G Kench, Margaret Gardiner-Garden, Phillip D Stricker, Howard I Scher, John J Grygiel, David B Agus, David H Mack, Robert L Sutherland.   

Abstract

Current models of prostate cancer classification are poor at distinguishing between tumors that have similar histopathological features but vary in clinical course and outcome. Here, we applied classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen (PSA) levels from each patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to PSA concentration. Three of approximately 200 probesets showing strongest correlation with relapse were identified as the gene for the putative calcium channel protein, trp-p8, with loss of trp-p8 mRNA expression associated with a significantly shorter time to PSA relapse-free survival. We observed subsequently that trp-p8 is lost in the transition to androgen independence in a prostate cancer xenograft model and in prostate cancer tissue from patients treated preoperatively with antiandrogen therapy, suggesting that trp-p8 is androgen regulated, and its loss may be associated with more advanced disease. The identification of trp-p8 and other proteins implicated in the phosphatidylinositol signal transduction pathway that are associated with prostate cancer outcome, both here and in other published work, suggests an integral role for this pathway in prostate carcinogenesis. Thus, our findings demonstrate that multivariable survival analysis can be applied to gene expression profiles of prostate cancers with censored follow-up data and used to identify molecular markers of prostate cancer relapse with strong predictive power and relevance to the etiology of this disease.

Entities:  

Mesh:

Year:  2003        PMID: 12874026

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

Review 1.  Tissue microarrays.

Authors:  Susan Henshall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

2.  V-ATPase subunit ATP6AP1 (Ac45) regulates osteoclast differentiation, extracellular acidification, lysosomal trafficking, and protease exocytosis in osteoclast-mediated bone resorption.

Authors:  De-Qin Yang; Shengmei Feng; Wei Chen; Haibo Zhao; Christie Paulson; Yi-Ping Li
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

Review 3.  Role of TRP ion channels in cancer and tumorigenesis.

Authors:  George Shapovalov; Abigael Ritaine; Roman Skryma; Natalia Prevarskaya
Journal:  Semin Immunopathol       Date:  2016-02-03       Impact factor: 9.623

4.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Regulation of TRPM8 channel activity.

Authors:  Yevgen Yudin; Tibor Rohacs
Journal:  Mol Cell Endocrinol       Date:  2011-10-28       Impact factor: 4.102

6.  Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells.

Authors:  Zhong-Hua Yang; Xing-Huan Wang; Huai-Peng Wang; Li-Quan Hu
Journal:  Asian J Androl       Date:  2009-02-23       Impact factor: 3.285

7.  The TRPM8 protein is a testosterone receptor: I. Biochemical evidence for direct TRPM8-testosterone interactions.

Authors:  Swapna Asuthkar; Pia A Elustondo; Lusine Demirkhanyan; Xiaohui Sun; Padmamalini Baskaran; Kiran Kumar Velpula; Baskaran Thyagarajan; Evgeny V Pavlov; Eleonora Zakharian
Journal:  J Biol Chem       Date:  2014-12-05       Impact factor: 5.157

8.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Authors:  Alison Y Zhang; Karen Chiam; Ygal Haupt; Stephen Fox; Simone Birch; Wayne Tilley; Lisa M Butler; Karen Knudsen; Clay Comstock; Krishan Rasiah; Judith Grogan; Kate L Mahon; Tina Bianco-Miotto; Carmela Ricciardelli; Maret Böhm; Susan Henshall; Warick Delprado; Phillip Stricker; Lisa G Horvath; James G Kench
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

10.  Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo.

Authors:  Guangbin Zhu; Xinghuan Wang; Zhonghua Yang; Hong Cao; Zhe Meng; Yongzhi Wang; Dong Chen
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.